相关实验视频

Updated: Jun 28, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

对肺大细胞神经内分泌癌的新辅助免疫化学疗法:病例报告

Chang Xu¹, Guangyin Zhao¹, Hongyu Zhang¹

¹Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.

Journal of cardiothoracic surgery

|April 14, 2024

概括

一种罕见的,激进的癌症,肺大细胞神经内分泌癌 (pLCNEC),在新辅助化疗和 pembrolizumab.com 治疗后显示出主要的病理缓解. 这种组合疗法为pLCNEC患者提供了一个有前途的治疗选择.

科学领域:

在瘤学瘤学.
肺部医学肺部医学
免疫治疗是一种免疫疗法.

背景情况:

肺大细胞神经内分泌癌 (pLCNEC) 是一种罕见且具有高复发率的侵袭性肺癌.
对于pLCNEC没有标准治疗方法,需要新的治疗策略.

研究的目的:

报告临床阶段IIB pLCNEC的新辅助治疗方法.
在pLCNEC中评估结合化疗与pembrolizumab的疗效和安全性.

主要方法:

一名64岁的男性有严重吸烟史,被诊断患有临床阶段IIB pLCNEC.
该患者在手术切除之前接受了两轮新辅助化疗与布罗利祖马布联合.
进行了39个月的术后监测.

主要成果:

新辅助治疗导致了显著的病理反应,实现了重大病理缓解 (MPR).
患者在手术后的39个月内没有复发.
这种治疗方案被患者耐受得很好.

结论:

这一案例代表了首次报告成功使用新辅助化疗与 pembrolizumab 的pLCNEC.
这种组合疗法显示出作为pLCNEC可行的治疗选择的潜力.
对这种pLCNEC的治疗方法进行进一步的研究是有必要的.

关键词:

案例报告案例报告在MPR中,MPR是MPR.新辅助免疫化学疗法新辅助免疫化学疗法在pLCNECEC中使用.

更多相关视频

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.